Most biotech CEOs act like science is a lottery. The edge isn’t predicting biology—it’s running unlimited, budget-disciplined experiments. This memo outlines why building a Continuous Experiment Engine is now the only viable path to scale, investor readiness, and a genuine competitive advantage.